Home / Transcripts / Heron Therapeutics, Inc. (HRTX) · August 10, 2026

Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript

August 10, 2026

NASDAQ US Health Care Biotechnology earnings 18 min

Earnings Call Speaker Segments

Executive executive
#1

Thanks, Operator, and hello everyone on this morning's call. We're glad you could be with us for Heron Therapeutics' discussion today, covering the financial results that the company reported for the second quarter of 2026. On the line from Heron are our Chief Executive Officer, Craig Collard; Ira Duarte, who serves as Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; Mark Hensley, our Chief Operating Officer; and Kevin Warner, Senior Vice President, Medical Affairs Strategy and Engagement. If you're participating conference call. A webcast will display the slides, and once we finish today, you'll also be able to find them on the investor relations section of our website. Before we begin, I'd like to take a moment to remind everyone that forward-looking statements will be made by the company during this conference call. Please be aware that anything we say that does not describe a historical fact is considered a forward-looking statement. This includes anything we say about the company's projections, expectations, plans, beliefs, and future performance, and all of these qualify as forward-looking statements under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. Statements of this kind are based on judgment and analysis as of today's date, and they carry a number of significant risks and uncertainties that may lead actual results to differ materially from what those statements describe. Details about the dangers and unknowns tied to the predictive remarks given during this conference call and webcast can be found in the safe harbor statement included in today's press release, as well as in Heron's public periodic filings with the SEC. Unless the law demands it, Heron takes on no duty to revise these predictive remarks so they mirror later occurrences or real results, and has no plan to do so. Having said that, I would like to turn the call over now to Craig Collard, Heron's Chief Executive Officer.

Craig Collard executive
#2

Thank you, Melissa. Hi, everybody, and thanks for joining the second quarter 2026 earnings call for Heron Therapeutics. Revenue on a net basis came to $37.7 million for the quarter; that represents an increase over the first quarter, yet it falls short of the bar we set for ourselves. Sinfanti sales rose versus Q1 in a market where competition is fierce, and Zendalev posted 35% growth year-over-year, though both trailed our expectations. Moving to slide four, I'll take you through the quarter's key updates. The acute care franchise posted 44% year-over-year revenue growth. ZMLF was up 35%, as average daily units climbed 19% year-over-year. Aponvy rose 74% year-over-year and achieved a 23% share within the surgical NK1 segment, gaining two points over the first quarter. And Sylvani landed at $21.8 million, an increase from $20.5 million in Q1. Mark will share further detail shortly regarding commercial performance. Past the commercial numbers, what I'd like to devote the remainder of my time today to is our response to the quarter and the path we're taking going forward. To begin, we reset the balance sheet. As disclosed today, we amended our credit facility with Hercules. When the ruling from the US District Court for the District of Delaware on certain patents covering Sylvante shifted the company's outlook, we approached our lender. This amendment aligns our covenants through 2027 with our new plan and brings down our principal. The terms appear in the filing. Next, we tightened our spending. Following the June court decision, we halted the Salesforce expansion that had been planned for this year's second half, and we are keeping a tight hold on spending while the competitive picture becomes clearer. Our spending choices track what the business shows us, rather than a plan that events have rendered obsolete. Third, we are protecting our oncology franchise. An appeal has been filed in response to the June decision. No generic has launched, but we are getting ready for possible generic competition to Symbante. Our defense strategy centers on the product's clinical profile, our customer relationships, and our contracting position, and we are carrying it out now, ahead of when it was needed. Finally, we are evaluating strategic alternatives even as we keep executing our current plan. No timetable has been established by the company for this process. There is no guarantee it will lead to any transaction, and the company has no intention of commenting further on these matters unless and until it concludes that more disclosure is appropriate or legally required. Before handing things to Mark, I want to acknowledge the whole Heron team; this stretch has been demanding, with a tough quarter, a court ruling we disagree with, and plenty of change, and through all of it this team has remained focused on patients and customers.

Mark Hensley executive
#3

At this point I'll pass it along to Mark, and he'll take us through the commercial performance. Over to you, Mark. Thanks, Craig. On slide six, I'll start with the overall net sales figure, which was $37.7 million in the second quarter, versus $34.7 million in the first quarter. Of that total, acute care was 15.3 million. Zinnerleff added 11.1 million, up from the 10.2 million posted earlier, and Oponvy was 4.2 million, compared with 3.4 million previously. Oncology as a whole brought in 22.3 million. Sinvanti accounted for 21.8 million, while Sustol was 0.5 million as the deliberate wind down proceeds. Ordering and channel dynamics are always moving quarter to quarter. A better read on adoption comes from average daily units and ordering accounts, so that's what I'll focus on. Turning to slide 7, there are two charts. Average daily units are on the left, ordering accounts on the right, and both continue to move upward. Net sales were $11.1 million, up 9% from the first quarter and up 35% from a year ago. The number I'd anchor on is demand. Average daily units increased 19% year over year, and lastly, Ignite 2.0 is now live in 3,150 accounts, up from 2,260 in Ignite 1.0. Adoption here is still happening site by site and case by case. Unit growth in the quarter was real, but it was below the pace we'd planned, so the work ahead is converting that access into cases and protocols inside accounts where we're already present. Let's turn to Oponvy. Here are those same two views for Oponvy, and both charts show a consistent rise. Net sales were about 4.2 million, up 74% from a year ago and up 26% from the first quarter. In the NK1 category, share reached 23%, an increase of two points from the previous period. Average daily units rose 59% year over year, while ordering accounts in June were up 42% versus June last year. P&T approvals now stand at 1,810 accounts, which represent 6.7 medium- to high-risk procedures each year. Demand was steady through the quarter. Now to Sinvanti. On the left, average daily units have held a stable level of utilization over the past two years, and on the right, ordering accounts were 1,241 in June, in line with a 12-month average of about 1,200. Net sales were 21.8 million, above the 20.5 million reported in the first quarter but down roughly 10 percent from a year ago; that year-over-year decline reflects the branded competition we've discussed on prior calls. More recently, the trend has been stable. Utilization has held steady, and share in June was 25%, in line with its 12-month average. The REIGNITE initiative around formulary position and our contracting relationships are the levers we control, and they're the foundation for how we'd compete with any future entrant. And lastly, Sustol continues its planned decline, in line with the remarks we've made on earlier calls. That wraps up the commercial portion: for Zinrillef, average daily units were up 19% compared with the prior year. Opambe took a 23% share within the NK1 segment. Sinvanti was down versus last year owing to rivals among branded products, although across the most recent two months its level has held steady. Beyond that, our work to safeguard contracts and manage formulary issues is complete. Across 6.7 million medium- to high-risk procedures each year, these efforts remain essential.

Ira Duarte executive
#4

So that's where demand stands right now. At this point I'll hand things over to Ira, who will walk through the financials. Over to you, Ira. Thanks, Mark. Craig already went through the quarter itself. What we can control is the way we run the business in response, and keeping tight discipline over our balance sheet and our spending is what matters going forward. The complete results appear on this slide. Let me walk through the highlights. Net revenues came to $37.7 million for the quarter, versus $34.7 million in the first quarter of 2026 and $37.2 million in the same quarter a year earlier, with gross margin at 69.3%. R&D expense totaled $2.7 million, while SG&A expense came to $25.4 million, which puts total operating expenses at $28.1 million, inclusive of stock-based compensation and depreciation. We posted an operating loss of $2 million and a net loss of $5.5 million, against a net loss of $2.4 million in the comparable prior year quarter. Adjusted EBITDA reached $3.2 million, an increase from $2.2 million in the comparable prior year quarter. We closed the quarter holding $42.7 million in cash, cash equivalents, and short-term investments. Following the June court decision, we worked out an amendment with our lender that waives the June 30th covenants and resets the schedule so it aligns with our operating plan. Under that amendment, we agreed to a principal reduction structured in two steps: $13.5 million paid when the amendment was executed, plus associated fees, and a possible additional $4 million reduction due on or before September 15th, for a potential total principal reduction of $17.5 million. Taking those payments into account, our pro forma cash sits at roughly $28.5 million, and roughly $24.3 million once the September payment is made. The amendment establishes monthly minimum revenue and EBITDA covenants running through December 2027, as well as a minimum cash covenant, and the agreement has been filed with our 10-Q. We are pulling our full year 2026 guidance of $173 to $183 million in net product sales and $10 to $20 million in adjusted EBITDA. Several factors make an annual figure unreliable at this moment, and none of them relates to a single quarter. First, the June court decision. When potential generic entry against Cervantes, our largest product, might happen and on what terms is not something we can forecast, and any annual figure would bake in an assumption we are not positioned to make. Second, the steps we took ourselves following that decision. We halted the salesforce expansion our plan had assumed for the second half, and we tightened spending. That prior guidance rested on that investment plan, and that is not the plan we are executing on now. Third, as Craig noted, we are evaluating strategic alternatives, something our amended credit agreement also reflects. Any one of these factors alone would make an annual figure unreliable; this is a forecasting decision, not a statement about the underlying business. We would reach the same decision no matter what the quarter's results turned out to be. Rather than providing guidance, each quarter we'll be reporting where our cash stands, what we're spending, and how we're doing on covenant compliance. With that said, let's open things up for questions.

Executive executive
#5

Hi there, and thanks for taking the question. I think I've got just 3 things for you. Could you say more about how confident you feel regarding meeting the updated debt covenants? In the scenario where a Sylvante generic comes to market? Maybe I'll stay with Sylvante. If and when a generic does show up, is there any reason the erosion shouldn't look like the Sustell erosion curve? And then maybe just on Sylvante. You were talking about Zen Relief, right? So you mentioned it came in below expectations; so could you help us think through what's behind this blue low expectation, this recent performance, you know, disurgence... just not sort of warm to the detail? Are they simply very sticky about the alternatives they use? Just any drive and color about, you know, what the hurdle is there in Zend relief? And possibly, I mean, what could a strategic partner who's well-capitalized do differently, something in the range of $10 million to $20 million in adjusted EBITDA? Thank you.

Craig Collard executive
#6

Absolutely, Brandon. I’ll start with the amended Hercules agreement. When we assessed Cervantes, we once more adopted a highly cautious view regarding the generic entry. In truth, multiple elements come into play here. To begin with, we have no clarity on the timing of when that product reaches the market. We recognize that this product carries certain production difficulties, since we handle those processes ourselves. It involves a sterile method. It is an emulsion. Consequently, scaling everything up sufficiently to satisfy market demand requires time; also remember, we are shifting roughly 750,000 to 800,000 units annually; therefore I doubt anybody would want to launch at that volume. Next comes the reimbursement aspect. You know, will they be classified under our J code, or will they get a separate J code? And once again, that factor can influence share too; plus it might alter the overall market dynamic; so many variables are in motion, yet our perspective treated this as a highly cautious, earlier launch type of case involving Hercules on the Covenant; so once more, I believe we are well protected there, since I genuinely think this could stretch longer than what we perhaps projected. And thus, from that angle, our lenders were quite at ease.

Mark Hensley executive
#7

I want to add a comment regarding the second item, ZENERLEF, and what happened during the quarter. Yes, and I appreciate the question, Brandon. Regarding ZENERLEF, the product's sequential growth came in at 9%. As you know, during Q1, the market as a whole declined. So we anticipated bouncing back from that quite robustly in Q2. Our second-quarter results fell short of what we had hoped for, and that responsibility rests with us to correct. I wouldn't attribute it to anything specific about the product itself. The market is admittedly somewhat sluggish at this point in the year, and if you look back at slide seven in the earnings deck, there's a strong upward trend during the latter half of the year for the market as well as for other products in that space. So we continue to expect that will happen, though Q2 clearly falls on us when it comes to execution, and we'll aim to remedy it during the third quarter. Okay.

Executive executive
#8

Good morning, and thanks for taking my questions. So I guess the first one is for Craig, about potential generics in Venti. I realize there’s still some lack of clarity regarding a possible launch there, but my understanding is that you have a couple of settlement agreements around Syvente with some other players. I’m curious what the impact would be on those potential launches for those players if Azure already launches a generic product. And then second, regarding Zynraluf, maybe this one is for Mark — I’m just curious what you’re seeing when it comes to surgical volumes and the overall volume of procedures during the second quarter. I believe your competitor reported some macro volatility that affected healthcare spending. I’m just curious whether you’re seeing the same kind of thing. Thanks.

Craig Collard executive
#9

Yes, sir. As for Sylvante, whether it ends up launching or not, that has zero effect on the settlement. So nothing there is going to change.

Mark Hensley executive
#10

Now, regarding Zinalef, when it comes to broader macro effects — well, I'd say we kept gaining ground on P&T wins all through the quarter. So perhaps that situation didn't hit us quite as hard, or at minimum, I didn't catch much mention of it specifically. But honestly, it comes down to needing time for pull-through, right? A handful of items during the quarter moved along a bit more slowly than we'd anticipated, and obviously, we're hoping to watch those keep pulling through as we move into the back half of the year.

Craig Collard executive
#11

No, I appreciate all of you for being on this quarter's call, and we'll speak with you again in the next quarter. Thank you.

Operator operator
#12

Appreciate it, everyone. That brings today's presentation to a close. Thanks for taking part. At this point you're welcome to log off, and enjoy the rest of your day; this live transcript is produced automatically, with no human involvement or checking.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.